{
  "nctId": "NCT01214044",
  "briefTitle": "Circadian Effects of Escitalopram",
  "officialTitle": "Determination of the Circadian Resetting Effects of Escitalopram and Testing for Correlations Between Circadian Resetting and Antidepressant Effects",
  "protocolDocument": {
    "nctId": "NCT01214044",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2008-09-03",
    "uploadDate": "2019-03-05T17:21",
    "size": 347679,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT01214044/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "NA"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "NA",
  "interventionModel": "SINGLE_GROUP",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 19,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2008-05",
    "completionDate": "2011-12",
    "primaryCompletionDate": "2011-12",
    "firstSubmitDate": "2010-10-01",
    "firstPostDate": "2010-10-04"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* 18-65 years old\n* able to comply with requirements of the experimental protocol\n* competent to sign informed consent\n* have mild to severe major depressive disorder without psychotic features and without a seasonal pattern\n* currently be under the care of a licensed mental health care provider or primary care physician\n* Score \\> 7 when interviewed by a trained rater using the 21-Item Hamilton Depression Scale (HAM-D)\n* be in good physical health\n* not be suicidal\n* not be taking any other antidepressant medications besides escitalopram during the study\n* be free of antidepressant medications for 2-4 weeks prior to beginning the study\n* not have a history of transmeridian travel or shift work in the past 2 months and have no plans for transmeridian travel or shift work for the duration of the study\n* be able to maintain a regular sleep wake schedule for the weeks one and nine of study\n* women of childbearing potential must have a negative pregnancy test and practice an acceptable method of birth control\n\nExclusion Criteria:\n\n* abnormal heart, liver, or kidney function\n* significant laboratory abnormalities on Complete Blood Count, Complete Metabolic Set, Thyroid Stimulating Hormone, EKG, \\& urinalysis\n* shift work or transmeridian travel in the last 2 months\n* current use of melatonin\n* evidence of a primary sleep disorder by history\n* women who are pregnant or lactating\n* be taking medications with known sedative or stimulating effects or that would interfere with the production of melatonin",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "65 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Change in Dim Light Melatonin Onset",
        "description": "The Dim Light Melatonin Onset (DLMO) is the time of the onset of melatonin secretion under dim light conditions using the equivalent thresholds of 10 pg/ml in plasma and 3 pg/ml in saliva. It is a marker of biological time. Data are provided in decimal and military time (e.g., 9:30 pm equals 21.50).\n\nThis measure is used to determine if there was a change in the time of the dim light melatonin onset (DLMO) before treatment with escitalopram (at Study Visit 3) and after treatment with escitalopram (at Study Visit 11).",
        "timeFrame": "8 Weeks: Study Visit 3 (after 1 week of placebo) to study Visit 11 (after 8 weeks of escitalopram)"
      }
    ],
    "secondary": [
      {
        "measure": "Change in Hamilton Depression Rating Scale (HAM-D) Scores",
        "description": "The HAM-D is the total score on the 21-question Hamilton Depression Rating Scale. Scores range from 0 to 53 with higher scores indicating worse symptoms of depression.",
        "timeFrame": "8 Weeks: Study Visit 3 (after 1 week of placebo) to study Visit 11 (after 8 weeks of escitalopram)"
      },
      {
        "measure": "Change in Beck Depression Inventory II (BDI-II) Scores",
        "description": "The BDI-II is the total score on the 21-question Beck Depression Inventory II questionnaire. Scores range from 0 to 63 with higher scores indicating worse symptoms of depression.",
        "timeFrame": "8 Weeks: Study Visit 3 (after 1 week of placebo) to study Visit 11 (after 8 weeks of escitalopram)"
      },
      {
        "measure": "Change in Phase Angle Difference (PAD)",
        "description": "The PAD is the time interval (number of hours) between the Dim Light Melatonin Onset (DLMO) and the average midpoint of sleep during the prior week. Larger PADs indicate a longer time interval between the DLMO and midpoint of sleep. A negative change in PAD value indicates a shortening of the time interval from Study Visit 3 to Study Visit 11.",
        "timeFrame": "8 Weeks: Study Visit 3 (after 1 week of placebo) to study Visit 11 (after 8 weeks of escitalopram)"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 3,
      "otherCount": 0,
      "totalCount": 4
    },
    "studyDesign": {
      "phases": [
        "NA"
      ],
      "isRandomized": false,
      "isMasked": false,
      "interventionModel": "SINGLE_GROUP"
    },
    "overallComplexityScore": 29,
    "complexityCategory": "Moderate"
  },
  "collectionDate": "2025-09-22T02:29:18.684Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}